Posters

Using AI-based quantification of PSMA expression on pre-and post-treatment 68Ga-PSMA11-PETs, we observe:1. Associations between PSMA PET SUV and response by both overall survival (OS) and PSA response. 2. Associations between degree of PSMA PET SUV in PSMA-expressing non-tumor tissues and adverse events (AEs). Expansion and refinement of this algorithm may improve our ability to anticipate toxicity by body-wide PSMA detection and predict treatment response.

Analysis and quantification of 18 F]F AraG PET using TRAQinform IQ technology provides patient level assessment of all areas with tracer uptake and may allow for better understanding of heterogeneity of T cell activation and potentially offer a more comprehensive evaluation of response to immunotherapy than the standard, tumor centric, radiologic methods.

Detection and quantification of amyloid burden in the heart is an unmet clinical need for patients with diverse forms of systemic amyloidosis. Given the heterogeneous presentation of cardiac disease in this patient population, if the evuzamitide radiotracer is approved for clinical use, this automated approach to image analysis could be an invaluable tool for novice readers, especially to quantify amyloid burden longitudinally without introducing reader bias.

Cancer is a dynamic disease which, over time, may result in nonuniform distribution of distinct tumor cell subpopulations at different sites (spatial heterogeneity) or an increase in molecularly diverse cells (temporal heterogeneity). Here we report the exploratory objectives of tumor burden and CTC analysis using QTBI and VERSA in men with mCRPC to bone treated with enzalutamide.

18F-NaF positron emission tomography/computed tomography (PET/CT) scan is an approved tool to detect and evaluate osteoblastic metastases that is more sensitive and specific than conventional bone scintigraphy. Here we assess the proportion of men treated with enzalutamide with responding lesions by 18F-NaF PET/CT scan at the time of prostate-specific antigen (PSA), standard radiographic, or clinical progression.

The purpose of this investigation was to understand and quantify the inter-lesion heterogeneity in treatment response seen on 68Ga-DOTATATE PET/CT imaging over the course of Lutathera therapy